Dopamine and 5-hydroxytryptamine signaling pathways in the pathogenesis of spinal cord injury-induced osteoporosis: new theory and novel therapeutic strategies

doi:10.3969/j.issn.2095-4344.2016.51.020

Abstract

Abstract:

BACKGROUND: Current basic and clinical research have showed that increases in bone resorption and bone loss accur earlier after spinal cord injury (SCI) than disuse atrophy, revealing that other mechanisms are involved in the pathogenesis of the SCI-induced osteoporosis (SIO).
OBJECTIVE: To introduce the current lab and clinical research progress in SIO focusing on the functional changes of two major neurotransmitters in the spinal cord, including dopamine (DA), 5-hydroxytryptamine (5-HT) and their receptors, as well as their regulatory functions on bone metabolism, aiming at finding a new treatment strategy for SIO.
METHODS: A computer-based online search in PubMed and Embase databases was conducted for clinical and basic research related to SIO published from January 1967 to August 2016, using the keywords of “spinal cord injury; osteoporosis; dopamine; serotonin; 5-hydroxytryptamine” in English. Irrelevant, poorly related and repetitive studies were excluded, and finally 41 eligible articles were included.
RESULTS AND CONCLUSION: DA and 5-HT are major neurotransmitters in the central nervous system, both involving in the regulation of bone remodeling. After SCI, loss of innervation and descending neurotransmitters especially DA, 5-HT and subsequent deregulation of their receptors are responsible for the onset of post-traumatic bone loss. The above research progress, in combination with the emerging clinical and lab investigations targeting 5-HT, DA and their receptors for improving neural functions after SCI, provides possible therapeutic pathways for SIO.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Spinal Cord Injuries, Osteoporosis, Dopamine, Serotonin, Tissue Engineering

CLC Number:

R318

Zhang Miao, Zhang Xu-ran, Li Rui, Sun Yu. Dopamine and 5-hydroxytryptamine signaling pathways in the pathogenesis of spinal cord injury-induced osteoporosis: new theory and novel therapeutic strategies[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(51): 7731-7737.

Figures/Tables 1

References

[1] Pelletier CA, Dumont FS, Leblond J, et al. Self-report of one-year fracture incidence and osteoporosis prevalence in a community cohort of canadians with spinal cord injury. Top Spinal Cord Inj Rehabil. 2014; 20(4):302-309.

[2] Coupaud S, McLean AN, Purcell M, et al. Decreases in bone mineral density at cortical and trabecular sites in the tibia and femur during the first year of spinal cord injury. Bone. 2015;74:69-75.

[3] Gifre L, Vidal J, Carrasco J, et al. Incidence of skeletal fractures after traumatic spinal cord injury: a 10-year follow-up study. Clin Rehabil. 2014;28(4):361-369.

[4] Jiang SD, Jiang LS, Dai LY. Mechanisms of osteoporosis in spinal cord injury. Clin Endocrinol (Oxf). 2006;65(5):555-565.

[5] Galea MP. Spinal cord injury and physical activity: preservation of the body. Spinal Cord. 2012;50(5): 344-351.

[6] Dolbow DR, Gorgey AS, Daniels JA, et al. The effects of spinal cord injury and exercise on bone mass: a literature review. NeuroRehabilitation. 2011;29(3): 261-269.

[7] Chang KV, Hung CY, Chen WS, et al. Effectiveness of bisphosphonate analogues and functional electrical stimulation on attenuating post-injury osteoporosis in spinal cord injury patients- a systematic review and meta-analysis. PLoS One. 2013;8(11):e81124.

[8] Nyandege AN, Slattum PW, Harpe SE. Risk of fracture and the concomitant use of bisphosphonates with osteoporosis-inducing medications. Ann Pharmacother. 2015;49(4):437-447.

[9] McGreevy C, Williams D. Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf. 2011; 2(4):159-172.

[10] Beggs LA, Ye F, Ghosh P, et al. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss. J Bone Miner Res. 2015;30(4):681-689.

[11] Maïmoun L, Couret I, Mariano-Goulart D, et al. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. Calcif Tissue Int. 2005;76(6):404-411.

[12] Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.

[13] Morse LR, Sudhakar S, Danilack V, et al. Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res. 2012;27(2):352-359.

[14] Garland DE, Stewart CA, Adkins RH, et al. Osteoporosis after spinal cord injury. J Orthop Res. 1992;10(3):371-378.

[15] Jiang SD, Yang YH, Chen JW, et al. Isolated osteoblasts from spinal cord-injured rats respond less to mechanical loading as compared with those from hindlimb-immobilized rats. J Spinal Cord Med. 2013; 36(3):220-224.

[16] Karsenty G, Yadav VK. Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu Rev Med. 2011;62:323-331.

[17] Amireault P, Sibon D, Côté F. Life without peripheral serotonin: insights from tryptophan hydroxylase 1 knockout mice reveal the existence of paracrine/autocrine serotonergic networks. ACS Chem Neurosci. 2013;4(1):64-71.

[18] Ghosh M, Pearse DD. The role of the serotonergic system in locomotor recovery after spinal cord injury. Front Neural Circuits. 2015;8:151.

[19] Haney EM, Warden SJ. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact. 2008;8(2):133-145.

[20] Ducy P. 5-HT and bone biology. Curr Opin Pharmacol. 2011;11(1):34-38.

[21] Karsenty G, Gershon MD. The importance of the gastrointestinal tract in the control of bone mass accrual. Gastroenterology. 2011;141(2):439-442.

[22] Westbroek I, van der Plas A, de Rooij KE, et al. Expression of serotonin receptors in bone. J Biol Chem. 2001;276(31):28961-28968.

[23] Cosentino M, Marino F, Maestroni GJ. Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives. Front Cell Neurosci. 2015;9:302.

[24] Lambert AM, Bonkowsky JL, Masino MA. The conserved dopaminergic diencephalospinal tract mediates vertebrate locomotor development in zebrafish larvae. J Neurosci. 2012;32(39): 13488-13500.

[25] Cobacho N, de la Calle JL, Paíno CL. Dopaminergic modulation of neuropathic pain: analgesia in rats by a D2-type receptor agonist. Brain Res Bull. 2014;106:62-71.

[26] Ondo WG, He Y, Rajasekaran S, et al. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord. 2000;15(1): 154-158.

[27] Miyake H, Nagashima K, Onigata K, et al. Allelic variations of the D2 dopamine receptor gene in children with idiopathic short stature. J Hum Genet. 1999;44(1): 26-29.

[28] Yamada Y, Ando F, Niino N, et al. Association of a polymorphism of the dopamine receptor D4 gene with bone mineral density in Japanese men. J Hum Genet. 2003;48(12):629-633.

[29] Hanami K, Nakano K, Saito K, et al. Dopamine D2-like receptor signaling suppresses human osteoclastogenesis. Bone. 2013;56(1):1-8.

[30] Hanami K, Nakano K, Tanaka Y. Dopamine receptor signaling regulates human osteoclastogenesis. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(1):35-39.

[31] Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone. 2012;51(3): 606-613.

[32] Eom CS, Lee HK, Ye S, et al. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res. 2012; 27(5): 1186-1195.

[33] Tsapakis EM, Gamie Z, Tran GT, et al. The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry. 2012;27(3):156-169.

[34] Meyer JM, Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry. 2006;18(1):43-48.

[35] Wang M, Hou R, Jian J, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol. 2014;29(2):183-189.

[36] O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(2 Suppl): 70-75.

[37] Kunimatsu T, Kimura J, Funabashi H, et al. The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats. Regul Toxicol Pharmacol. 2010;58(3):360-368.

[38] Lapointe NP, Guertin PA. Synergistic effects of D1/5 and 5-HT1A/7 receptor agonists on locomotor movement induction in complete spinal cord-transected mice. J Neurophysiol. 2008;100(1):160-168.

[39] Lapointe NP, Rouleau P, Ung RV, et al. Specific role of dopamine D1 receptors in spinal network activation and rhythmic movement induction in vertebrates. J Physiol. 2009;587(Pt 7):1499-1511.

[40] Jiang W, Huang Y, He F, et al. Dopamine D1 Receptor Agonist A-68930 Inhibits NLRP3 Inflammasome Activation, Controls Inflammation, and Alleviates Histopathology in a Rat Model of Spinal Cord Injury. Spine (Phila Pa 1976). 2016;41(6):E330-334.

[41] Ganzer PD, Manohar A, Shumsky JS, et al. Therapy induces widespread reorganization of motor cortex after complete spinal transection that supports motor recovery. Exp Neurol. 2016;279:1-12.

[42] Cornide-Petronio ME, Fernández-López B, Barreiro-Iglesias A, et al. Traumatic injury induces changes in the expression of the serotonin 1A receptor in the spinal cord of lampreys. Neuropharmacology. 2014;77:369-378.

[43] Murray KC, Stephens MJ, Ballou EW, et al. Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity. J Neurophysiol. 2011;105(2):731-748.

[44] S?awińska U, Miazga K, Jordan LM. 5-HT? and 5-HT? receptor agonists facilitate plantar stepping in chronic spinal rats through actions on different populations of spinal neurons. Front Neural Circuits. 2014;8:95.

[45] Demirel G, Yilmaz H, Paker N, et al. Osteoporosis after spinal cord injury. Spinal Cord. 1998;36(12):822-825.

[46] Ducy P, Karsenty G. The two faces of serotonin in bone biology. J Cell Biol. 2010;191(1):7-13.

[47] Otake T, Ieshima H, Ishida H, et al. Bone atrophy in complex regional pain syndrome patients measured by microdensitometry. Can J Anaesth. 1998;45(9): 831-838.